Lakefront Biotherapeutics | GLPG - Current Liabilities


Lakefront Biotherapeutics reported EUR100.42M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
Genmab DKK 1.43B 686M Dec/2025
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
GRIFOLS EUR 2.24B 112M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Incyte USD 1.31B 177.55M Jun/2026
Merck EUR 9.35B 307M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
UCB EUR 4.4B 470M Dec/2025
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026